SCHEMBL1067152

SCHEMBL1067152

CC(=O)OCCc1ccc(Cl)cc1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SIRT2 Q8IXJ6 1/20 0.47
CNR1 P21554 3/20 0.45
POLB P06746 2/20 0.45
CYP1A2 P05177 1/20 0.45
CYP2D6 P10635 1/20 0.45
CYP2C19 P33261 1/20 0.45
KDM4E B2RXH2 1/20 0.45
ALDH1A1 P00352 1/20 0.45
GAA P10253 1/20 0.45
CTDSP1 Q9GZU7 1/20 0.45
PLAAT3 P53816 1/20 0.44
PLAAT5 Q96KN8 1/20 0.44
PLAAT2 Q9NWW9 1/20 0.44
PLAAT4 Q9UL19 1/20 0.44
MAOA P21397 1/20 0.44
MAOB P27338 1/20 0.44
FPR2 P25090 1/20 0.43
TSHR P16473 1/20 0.43
L3MBTL1 Q9Y468 1/20 0.43
TAAR1 Q96RJ0 2/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4242570 0.82 ALDH1A1 (0.62) KDM4EALDH1A1TSHRMEN1KMT2A
SCHEMBL2387794 0.82 NPC1 (0.57) KDM4EALDH1A1MAOBMEN1KMT2A
SCHEMBL8652676 0.82 LMNA (0.45) CYP1A2KDM4EALDH1A1CTDSP1MAOB
SCHEMBL86139 0.82 ALDH1A1 (0.47) ALDH1A1TSHRL3MBTL1TAAR1SMN1; SMN2
SCHEMBL27905842 0.82 POLB (0.47) POLBCYP1A2CYP2D6CYP2C19KDM4E
SCHEMBL148596 0.82 THRB (0.47) POLBCYP1A2CYP2D6CYP2C19KDM4E
SCHEMBL28327983 0.81 TSHR (0.51) POLBCYP1A2CYP2D6CYP2C19KDM4E
SCHEMBL10053298 0.81 L3MBTL1 (0.44) POLBKDM4EALDH1A1L3MBTL1LMNA
SCHEMBL5691929 0.81 ALDH1A1 (0.41) ALDH1A1TSHRL3MBTL1SMN1; SMN2MAPT
SCHEMBL86418 0.81 KMT2A (0.55) ALDH1A1GAAMAOAMAOBL3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-110590606-B Process for preparing pyrimidylcyclopentane compounds 豪夫迈·罗氏有限公司 2023-02-17 CN disclosed
CN-105899492-B Process for preparing pyrimidylcyclopentane compounds 豪夫迈·罗氏有限公司 2021-08-24 CN disclosed
CN-112898210-A Process for preparing pyrimidylcyclopentane compounds 豪夫迈·罗氏有限公司 2021-06-04 CN disclosed
CN-110590606-A Process for preparing pyrimidylcyclopentane compounds 豪夫迈·罗氏有限公司 2019-12-20 CN disclosed
CN-102015706-A Imidazolidinone derivatives as 11B-HSD1 inhibitors HOFFMANN LA ROCHE 2011-04-13 CN disclosed
US-20110007123-A1 THERMAL TRANSFER SHEET AND IMAGE FORMATION METHOD USING SAME FUJIFILM CORPORATION (JP) 2011-01-13 US disclosed
US-7825149-B2 Substituted imidazoles PFIZER LIMITED (GB) 2010-11-02 US disclosed
US-20090312326-A1 SUBSTITUTED IMIDAZOLES PFIZER LIMITED (GB) 2009-12-17 US disclosed
US-7592362-B2 Substituted imidazoles PFIZER LIMITED (GB) 2009-09-22 US disclosed
US-7547718-B2 Substituted imidazoles PFIZER LIMITED (GB) 2009-06-16 US disclosed
US-20080125473-A1 SUBSTITUTED IMIDAZOLES PFIZER LIMITED (GB) 2008-05-29 US disclosed
US-20080119536-A1 SUBSTITUTED IMIDAZOLES PFIZER LIMITED (GB) 2008-05-22 US disclosed
US-20070167506-A1 SUBSTITUTED IMIDAZOLES PFIZER INC. (US) 2007-07-19 US disclosed
CN-1882347-A AKT protein kinase inhibitors ARRAY BIOPHARMA INC (US) 2006-12-20 CN disclosed
CN-1151140-C Glucokinase activators - 2004-05-26 CN disclosed
CN-1349519-A Glucokinase activators HOFFMANN LA ROCHE (CH) 2002-05-15 CN disclosed
US-5846989-A Benzothiazolone derivatives ASTRA PHARMACEUTICALS LIMITED (GB) 1998-12-08 US disclosed
US-4339951-A Tempeature measurement and display of indicia using thermochromic polyacetylenes ALLIED CORPORATION (US) 1982-07-20 US disclosed
US-4242440-A Thermochromic polyacetylenes used in laser beam recording method ALLIED CHEMICAL CORPORATION (US) 1980-12-30 US disclosed
US-4215208-A Thermochromic polyacetylenes containing urethane groups ALLIED CHEMICAL CORPORATION (US) 1980-07-29 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080125473-A1 SUBSTITUTED IMIDAZOLES ABL1, TYR, CYP3A4 SIRT2 1457/4885CNR1 1586/4885POLB 3099/4885
US-20090312326-A1 SUBSTITUTED IMIDAZOLES ABL1, TYR, CYP3A4 SIRT2 1457/4885CNR1 1586/4885POLB 3099/4885
US-20070167506-A1 SUBSTITUTED IMIDAZOLES ABL1, TYR, CYP3A4 SIRT2 1457/4885CNR1 1586/4885POLB 3099/4885
US-20080119536-A1 SUBSTITUTED IMIDAZOLES ABL1, TYR, CYP3A4 SIRT2 1457/4885CNR1 1586/4885POLB 3099/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.